The most consequential trial in PTSD drug development right now is not a classic psychedelic, and that is the entire point of it. Transcend Therapeutics has opened EMPOWER-1, a Phase 3 study of TSND-201, a proprietary form of methylone, which is a close structural analog of MDMA. The program is built, almost feature for feature, as a response to why MDMA failed at the FDA, and a Japanese pharmaceutical company has paid more than a billion dollars on the bet that the response works.
The failure it is answering
In August 2024 the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD, issuing a complete response letter and asking for another Phase 3 trial. Among the problems the agency and its advisory committee raised, one was structural and hard to fix: functional unblinding. MDMA produces a subjective experience so unmistakable that participants and the therapists rating them could tell who had received the drug and who had received placebo, which undermined confidence that the measured benefit was the drug rather than expectation. It was the kind of problem that is not solved by running the same trial again, because it is baked into using a drug whose whole effect announces itself.
Methylone is a wager that the benefit can be kept while the announcing part is removed.
What methylone is
TSND-201 is Transcend’s proprietary formulation of methylone, which the company describes as a rapid-acting neuroplastogen. Mechanistically it is a monoamine releaser, increasing norepinephrine, serotonin, and dopamine through the transporters, and the critical detail is what it does not do: it has no meaningful activity at the 5-HT2A receptor, the site responsible for the hallucinogenic effects of classic psychedelics. Methylone is, in other words, an MDMA relative engineered to be non-hallucinogenic. The thesis is that the pro-plasticity, fear-extinction benefit associated with the MDMA class comes from the neuroplasticity it induces rather than from the subjective trip, and that you can therefore deliver the first without the second. Preclinical work supports the plausibility, showing methylone promotes neuronal growth and improves fear-extinction learning through neurotrophic signaling pathways.
The Phase 2 data are encouraging at a small scale. In the IMPACT-1 trial, 65 patients with severe PTSD received four oral doses of TSND-201 or placebo, and the drug met its primary endpoint with a placebo-adjusted improvement of 9.64 points on the clinician-administered PTSD scale at day 64, with separation visible as early as day 10. On that basis the FDA granted Breakthrough Therapy designation in July 2025 and a national priority voucher in April 2026, the same accelerated-review mechanism awarded to Compass Pathways’ psilocybin program. The Phase 3 EMPOWER-1 trial now enrolling is designed for 300 participants randomized to two doses of methylone or placebo, dosed four times across four weeks with an eight-week follow-up.
The validation, and the buyer
The clearest signal that this is a serious bet is the buyer. In March 2026, Otsuka agreed to acquire Transcend for $700 million upfront and up to $525 million in milestones, a total of as much as $1.225 billion. That is Big Pharma money on a single late-stage asset, and it places the de-risked entactogen approach inside a company assembling a neuropsychiatric portfolio. Otsuka is also the maker of Rexulti, the incumbent in Alzheimer’s agitation, which makes the methylone purchase part of a broader pattern worth tracking rather than a one-off.
Why the central claim is still unproven
The unblinding fix is the thesis of the whole program, and it has not been tested at scale. Non-hallucinogenic is not the same as non-perceptible. Methylone still raises norepinephrine, serotonin, and dopamine, still produces acute physiological effects, and the Phase 2 design used a split booster dose specifically to manage peak plasma concentrations and side effects, which is itself an acknowledgment that the acute effects are real. Whether participants and raters can still guess assignment, and whether that guessing inflates the result, is precisely what a 300-patient Phase 3 will reveal in a way that a 65-patient Phase 2 could not.
There is a deeper version of the same question. The MDMA-for-PTSD model paired the drug with extensive psychotherapy, and part of the long argument about those trials was how much of the benefit came from the drug, how much from the therapy, and how much from the experience itself. Methylone’s neuroplastogen thesis says the plasticity does the work and the experience is incidental. If that is wrong, if the subjective experience was carrying part of the therapeutic effect, then stripping it out could strip out some of the benefit along with the blinding problem. The trial is testing both possibilities at once.
And PTSD is unforgiving ground. Only two drugs are FDA-approved for it, both decades-old SSRIs, and the field is littered with failed trials and large placebo responses. A 9.64-point separation in 65 patients is a real signal and a small sample, and the history of this indication is that promising mid-stage effects often shrink in pivotal trials.
The frame
Methylone matters beyond its own prospects because it is the cleanest test yet of a specific post-Lykos hypothesis: that the therapeutic value of the MDMA class can be separated from the psychedelic experience, packaged as a conventional drug, and run through a conventional Phase 3 that the FDA can trust. If EMPOWER-1 reads out positive and the blinding holds, it becomes a template for an entire neuroplastogen-without-the-trip approach, and it vindicates Otsuka’s billion-dollar read. If the effect shrinks at scale, or the blinding breaks anyway, it suggests the experience and the benefit were harder to separate than the thesis assumes. The question methylone is really answering is the one Lykos left open: whether MDMA’s benefit in PTSD was real but unmeasurable because of the trip, or partly an artifact of it. The drug is built entirely on the first answer, and EMPOWER-1 is where that conviction meets data.